Teleflex (NYSE:TFX) Given New $175.00 Price Target at Royal Bank Of Canada

Posted by Geri Gentry on Nov 7th, 2026

Teleflex (NYSE:TFX – Free Report) had its price target hoisted by Royal Bank Of Canada from $155.00 to $175.00 in a research note published on Friday,Benzinga reports. They currently have an outperform rating on the medical technology company’s stock.

Several other research firms also recently commented on TFX. Truist Financial decreased their price target on shares of Teleflex from $150.00 to $142.00 and set a “hold” rating on the stock in a research note on Wednesday, October 14th. Bank of America raised shares of Teleflex from a “neutral” rating to a “buy” rating and increased their target price for the company from $145.00 to $158.00 in a report on Monday, September 28th. UBS Group boosted their price target on shares of Teleflex from $145.00 to $158.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 11th. Zacks Research cut Teleflex from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 23rd. Finally, Wall Street Zen upgraded Teleflex from a “sell” rating to a “hold” rating in a report on Sunday, August 9th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $160.80.

View Our Latest Research Report on Teleflex

Teleflex Price Performance

NYSE:TFX traded down $1.26 during midday trading on Friday, hitting $150.89. The company had a trading volume of 948,142 shares, compared to its average volume of 718,324. The company has a market capitalization of $6.39 billion, a PE ratio of 18.33, a P/E/G ratio of 0.94 and a beta of 0.85. The company has a quick ratio of 2.12, a current ratio of 2.60 and a debt-to-equity ratio of 0.94. Teleflex has a 52-week low of $100.18 and a 52-week high of $156.67. The stock’s fifty day moving average price is $132.15 and its 200-day moving average price is $126.09.

Teleflex (NYSE:TFX – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The medical technology company reported $2.63 earnings per share for the quarter, beating analysts’ consensus estimates of $1.90 by $0.73. Teleflex had a positive return on equity of 11.93% and a negative net margin of 39.67%. The business had revenue of $567.80 million for the quarter, compared to the consensus estimate of $565.52 million. During the same quarter last year, the business posted $3.67 earnings per share. The company’s revenue for the quarter was up .1% on a year-over-year basis. As a group, research analysts expect that Teleflex will post 7.22 earnings per share for the current year.

Teleflex Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 31st. Investors of record on Monday, November 16th will be issued a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Monday, November 16th. Teleflex’s payout ratio is currently -5.84%.

Hedge Funds Weigh In On Teleflex

Hedge funds have recently made changes to their positions in the business. Kelleher Financial Advisors purchased a new stake in Teleflex in the second quarter worth $25,000. Root Financial Partners LLC purchased a new position in Teleflex during the 3rd quarter valued at $27,000. Next Level Wealth Planning LLC bought a new position in Teleflex in the 3rd quarter worth $38,000. Heritage Family Offices LLP purchased a new stake in shares of Teleflex in the 3rd quarter worth about $39,000. Finally, Allworth Financial LP purchased a new stake in shares of Teleflex in the 2nd quarter worth about $44,000. 95.62% of the stock is owned by hedge funds and other institutional investors.

Teleflex News Roundup

Here are the key news stories impacting Teleflex this week:

Positive Sentiment: Royal Bank of Canada raised its price target to $175 from $155 and maintained an “outperform” rating, implying about 16% upside from the cited share price. Royal Bank of Canada rating
Positive Sentiment: Wells Fargo increased its target to $167 from $138, while keeping an “equal weight” rating. Mizuho also raised its target, to $160. Wells Fargo rating Mizuho price target
Positive Sentiment: Adjusted third-quarter EPS of $2.63 topped analyst estimates of about $1.90. Revenue of $567.8 million also narrowly exceeded expectations. Third-quarter results and outlook
Neutral Sentiment: Teleflex declared a quarterly dividend of $0.34 per share, equivalent to $1.36 annually and a yield of about 0.9%. Dividend announcement
Negative Sentiment: Revenue grew only 0.2% year over year, and adjusted EPS fell from $3.67 a year earlier. The modest reported growth may limit enthusiasm despite the earnings beat. Third-quarter results and outlook

Teleflex Company Profile

(Get Free Report)

Teleflex Incorporated is a global medical technology company that develops, manufactures and markets specialty medical devices. Its products are designed to support healthcare professionals in critical care and procedural settings, including vascular access, interventional cardiology and radiology, anesthesia, respiratory care, emergency medicine, surgical applications and urology.

The company’s portfolio includes catheters, access and closure devices, airway-management products, surgical instruments, pain-management devices and other technologies used in hospitals and outpatient facilities.